There have been no open-market insider trades at Jasper Therapeutics, Inc. in the last 12 months.
On the institutional side, 45 funds reported holding JSPR at the end of Q2 2026, and more funds sold than bought. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2025 | WIGGANS THOMAS G | Director | Buy | 41,000 | $2.43 | $100K | SEC |
| Sep 24, 2025 | Lucas Svetlana | Director | Buy | 20,000 | $2.43 | $49K | SEC |
| Sep 24, 2025 | MARTELL RON | CEO | Buy | 41,000 | $2.43 | $100K | SEC |
| Sep 24, 2025 | Shizuru Judith Anne | Director | Buy | 41,000 | $2.43 | $100K | SEC |
| Dec 12, 2024 | Mahal Jeetinder Singh | COO | Sell | 900 | $22.11 | $20K | SEC |
| Sep 12, 2024 | Mahal Jeetinder Singh | COO | Sell | 900 | $21.23 | $19K | SEC |
| Jun 12, 2024 | Mahal Jeetinder Singh | COO | Sell | 900 | $24.16 | $22K | SEC |
| Mar 12, 2024 | Mahal Jeetinder Singh | COO | Sell | 900 | $26.44 | $24K | SEC |
| Feb 12, 2024 | Abingworth LLP | 10% Owner | Buy | 190,000 | $12.95 | $2.5M | SEC |
| Feb 9, 2024 | VENKATARAMAN BALAJI | 10% Owner | Buy | 350,000 | $12.95 | $4.5M | SEC |
| Nov 30, 2023 | WIGGANS THOMAS G | Director | Buy | 10,000 | $0.65 | $6K | SEC |
| Nov 22, 2023 | WIGGANS THOMAS G | Director | Buy | 10,000 | $0.64 | $6K | SEC |
| Nov 20, 2023 | WIGGANS THOMAS G | Director | Buy | 10,000 | $0.60 | $6K | SEC |
| Nov 20, 2023 | WIGGANS THOMAS G | Director | Buy | 10,000 | $0.63 | $6K | SEC |
| Nov 20, 2023 | WIGGANS THOMAS G | Director | Buy | 10,000 | $0.60 | $6K | SEC |
There were no open-market insider trades in JSPR in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
45 investment managers reported holding JSPR in SEC Form 13F filings for Q2 2026.
No congressional trades in JSPR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).